Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ankit Bhatia

Advanced Heart Failure and Transplant Cardiology Cincinnati, OH Medical Doctor

NPI 1801200944 CMS profile 1239998

2123 Auburn Ave Ste 137, Cincinnati, OH 45219

Open in the dashboard

General payments

$141,200

281 records reported · program years 2019–2025

Research payments

$1,776

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$362,475 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Ankit Bhatia of Cincinnati, OH is reported in the CMS Open Payments database as having received $141,200 across 281 general payments and $1,776 in research payments paid to them. Separately, studies naming them as principal investigator received $362,475 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $56,630 83
2024 General $26,503 49
2024 Research $1,776 3
2023 General $40,749 81
2022 General $12,343 28
2021 General $2,923 10
2020 General $276 12
2019 General $1,777 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ankit Bhatia
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Ankit Bhatia were reported at $56,630. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Ankit Bhatia Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $1,777 $863 $224–$4,562 $163
2020 $276 $452 $122–$3,992 $114
2021 $2,923 $550 $159–$3,571 $132
2022 $12,343 $729 $221–$4,357 $149
2023 $40,749 $1,002 $309–$5,827 $160
2024 $26,503 $931 $273–$5,204 $164
2025 $56,630 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $124,009 106 payments
  2. Abbott Laboratories $7,546 114 payments
  3. Medtronic, Inc. $4,303 24 payments
  4. Boston Scientific Corporation $3,343 12 payments
  5. CVRx, Inc. $1,011 9 payments
  6. AstraZeneca Pharmaceuticals LP $259 3 payments
  7. Novo Nordisk Inc $149 3 payments
  8. Abiomed $147 1 payment
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $116 3 payments
  10. Genzyme Corporation $104 1 payment
  11. Other $214 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $105,545 23 payments
  2. Consulting Fee $13,350 9 payments
  3. Food and Beverage $10,255 181 payments
  4. Travel and Lodging $9,373 64 payments
  5. Grant $2,500 1 payment
  6. Education $178 3 payments
Products named General payments · program years 2019–2025
  1. CAMZYOS $117,154 89 payments
  2. SYNCHROMED $2,500 1 payment
  3. CARDIOMEMS Heart failure $2,085 41 payments
  4. CardioMEMS HF System $1,331 12 payments
  5. CARDIOMEMS Structural Heart $1,243 13 payments
  6. Barostim Neo System $1,011 9 payments
  7. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Heart failure $602 9 payments
  8. PROCLAIM $453 5 payments
  9. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Structural Heart $384 4 payments
  10. INTELLIS ADAPTIVESTIM $328 4 payments
  11. Other $2,761 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Lexicon Pharmaceuticals, Inc. $1,776 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

4,133

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$3,617,207

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

38%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Camzyos Mavacamten Brand 273 $2,228,913
Entresto Sacubitril/Valsartan Brand 368 $420,857
Jardiance Empagliflozin Brand 389 $404,037
Eliquis Apixaban Brand 241 $272,824
Ozempic Semaglutide Brand 60 $67,049
Repatha Sureclick Evolocumab Brand 42 $51,042
Xarelto Rivaroxaban Brand 34 $50,202
Farxiga Dapagliflozin Propanediol Brand 28 $42,185
Wegovy Semaglutide Brand 21 $32,271
Sildenafil Citrate Generic 11 $6,040

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$121,152

Medicare's payments for the services billed

Medicare patients

796

Average age 74

Services billed

2,386

348 women, 448 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 63%
Heart failure 62%
Arthritis 53%
Atrial fibrillation 50%
Chronic kidney disease 43%
Diabetes 38%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $23,896
$23,896 273 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $4
$4 241 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record